Antithrombotic therapies for neurointerventional surgery: a 2021 French comprehensive national survey

• DOI: 10.1136/neurintsurg-2021-018601
• Publication Date: 2022-03-28T17:26:37Z
• Authors: Jildaz Caroff; Laurent Aubert; Cécile Lavenu-Bom...; Samy Figueiredo; Kamelia Habchi; Jonathan Cortese; Francois Eugene; Julien Ognard; Florence Tahon; Géraud Forestier; Heloise Ifergan; François Zhu; Jean-Francois Hak; Anthony Reyre; Morgane Laubacher; Abdoulaye Traore; Jean Philippe Des...; Imad Derraz; Ricardo Moreno; Marc Bintner; Guillaume Charbon...; Anthony Le Bras; Louis Veunac; Florent Gariel; Hocine Redjem; Jacques Sedat; Guillaume Tessier; Victor Dumas; Maxime Gauberti; Cyril Chivot; Arturo Consoli; Nicolas Bricout; Titien Tuilier; Alexis Guedon; Raoul Pop; Pierre Thouant; Guillaume Bellanger; Riccardo Zannoni; Sebastien Soize; Johann Sebastian ...; Olivier Heck; Cristian Mihalea; Julien Burel; Jean-Baptiste Girot; Eimad Shotar; Sebastian Gazzola; Gregoire Boulouis; Basile Kerleroux
• Keywords: Platelets; Standards; MESH: Heparin; [SDV]Life Sciences [q-bio]; Intervention; MESH: Stroke; 03 medical and health sciences; MESH: Cross-Sectional Studies; 0302 clinical medicine; Fibrinolytic Agents; 616; MESH: Fibrinolytic Agents; Humans; MESH: Aspirin; Pharmacology; MESH: Humans; Aspirin; Heparin; 3. Good health; [SDV] Life Sciences [q-bio]; Stroke; Cross-Sectional Studies; MESH: Platelet Aggregation Inhibitors; Drug; [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology; Platelet Aggregation Inhibitors

Neurointerventionists lack guidelines for the use of antithrombotic therapies in their clinical practice; consequently, there is likely to be significant heterogeneity between centers. Through a nationwide survey, we aimed obtain an exhaustive cross-sectional overview neurointerventional procedures France.In April 2021, French surgery centers were invited participate 51-question survey disseminated through active trainee-led research collaborative network (the JENI-RC).All 40 answered survey. Fifty-one percent reported using ticagrelor and 43% used clopidogrel as premedication before intracranial stenting. For flow diversion treatment, dual antiplatelet therapy was maintained 3 or 6 months 39% 53% centers, respectively, aspirin prescribed 12 more than 63% 26% respectively. unruptured aneurysms, most common heparin bolus dose 50 IU/kg (59%), only 35% monitored activity adjustment. Tirofiban 64% treat thromboembolic complications. Fifteen these comprehensive stroke tenecteplase acute ischemic strokes. Cangrelor appeared emergent drug specific indications.This highlights important practices across There pressing need trials further evaluate harmonize regimens field.